Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Alice P. Chen; Elad Sharon; Geraldine O’Sullivan-Coyne; Nancy Moore; Jared C. Foster; James S. Hu; Brian A. Van Tine; Anthony P. Conley; William L. Read; Richard F. Riedel; Melissa A. Burgess; John Glod; Elizabeth J. Davis; Priscilla Merriam; Abdul R. Naqash; Kristin K. Fino; Brandon L. Miller; Deborah F. Wilsker; Asma Begum; Katherine V. Ferry-Galow; Hari A. Deshpande; Gary K. Schwartz; Brian H. Ladle; Scott H. Okuno; Jill C. Beck; James L. Chen; Naoko Takebe; Laura K. Fogli; Christina L. Rosenberger; Ralph E. Parchment; James H. Doroshow

Journal Article

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Chen A
Sharon E
O’Sullivan-Coyne G
et al.

New England Journal of Medicine (2023) 389(10) 911-921

DOI: 10.1056/nejmoa2303383

125Citations

85Readers

Get full text

Abstract

Abstract Background Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors...

Cite

CITATION STYLE

APA

Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., … Doroshow, J. H. (2023). Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal of Medicine, 389(10), 911–921. https://doi.org/10.1056/nejmoa2303383

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

Abstract

Cite

Register to see more suggestions